EUVIMEDEUVIMED entdecken
QuerschnittstudieOpen Access · CC BY 4.0

Determining sensitivity and specificity of risk scores for QTc interval prolongation in hemato-oncology patients prescribed systemic antifungal therapy: a retrospective cross-sectional study

Julian Steinbrech, Till Klein, Stephanie Kirschke, Hanna Mannell, Sebastian Clauß, Thilo Bertsche, Dorothea Strobach

International Journal of Clinical Pharmacy · 2024

DOI: 10.1007/s11096-024-01788-w ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift International Journal of Clinical Pharmacy, 2024. Verfasst von Julian Steinbrech und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Pharmacy, LMU University Hospital, Marchioninistr. 15, 81377, Munich, Germany. julian.steinbrech@med.uni-muenchen.de. Hauptthemen laut MEDLINE: Long QT Syndrome, Antifungal Agents, Electrocardiography, Hematologic Neoplasms. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Klinikum der Universität München.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

QTc interval prolongation can result in potentially lethal arrhythmias. One risk factor is QTc-prolonging drugs, including some antifungals often used in hemato-oncology patients. Screening tools for patients at risk have not yet been investigated in this patient population.

Aim

Our aim was to evaluate the sensitivity and specificity of five QTc risk scores in hemato-oncology patients receiving systemic antifungal therapy.

Method

Data were retrieved from an internal study database including adult hemato-oncology patients prescribed systemic antifungal therapy. Data on QTc-prolonging medication, risk factors for QTc prolongation, and electrocardiograms (ECG) were collected retrospectively for a period of 12 months. The QTc risk scores according to Tisdale, Vandael, Berger, Bindraban, and Aboujaoude as well as their sensitivity and specificity were calculated.

Results

During the evaluated period, 77 patients were prescribed systemic antifungals resulting in 187 therapy episodes. Regarding therapy episodes, median age was 56 years (IQR 44–68), 41% (77) were female, and a median of 3 QTc-prolonging drugs were prescribed (range 0–6). ECGs were available for 45 (24%) of the therapy episodes 3–11 days after initiation of the antifungal therapy, 22 of which showed QTc prolongation. Regarding these 45 therapy episodes, sensitivity and specificity of the risk scores were calculated as follows: Tisdale 86%/22%, Vandael 91%/35%, Berger 32%/83%, Bindraban 50%/78%, Aboujaoude 14%/87%.

Conclusion

The QTc risk scores according to Tisdale and Vandael showed sufficient sensitivity for risk stratification in the studied patient population. In contrast, risk scores according to Berger, Bindraban, and Aboujaoude cannot be considered suitable due to poor sensitivity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Long QT SyndromeAntifungal AgentsElectrocardiographyHematologic NeoplasmsHumansFemaleMaleRetrospective StudiesMiddle AgedAgedAdultCross-Sectional StudiesRisk FactorsSensitivity and SpecificityRisk Assessment

Stichwörter der Autor:innen

Antifungal agentsHemato-oncologyLong QT syndromePharmaceutical careRisk assessment

Substanzen

Antifungal Agents

Autor:innen und Institutionen

  • Hospital Pharmacy, LMU University Hospital, Marchioninistr. 15, 81377, Munich, Germany. julian.steinbrech@med.uni-muenchen.de.
  • Doctoral Program Clinical Pharmacy, LMU University Hospital, Marchioninistr. 15, 81377, Munich, Germany. julian.steinbrech@med.uni-muenchen.de.
  • Doctoral Program Clinical Pharmacy, LMU University Hospital, Marchioninistr. 15, 81377, Munich, Germany.
  • Hospital Pharmacy, LMU University Hospital, Marchioninistr. 15, 81377, Munich, Germany.
  • Department of Physiology, Institute for Theoretical Medicine, Faculty of Medicine, University of Augsburg, 86159, Augsburg, Germany.
  • Department of Cardiology, LMU University Hospital, Marchioninistr. 15, 81377, Munich, Germany.

Förderung

  • Klinikum der Universität München

Zitieren

APA

Steinbrech, J., Klein, T., Kirschke, S., Mannell, H., Clauß, S., Bertsche, T., & Strobach, D. (2024). Determining sensitivity and specificity of risk scores for QTc interval prolongation in hemato-oncology patients prescribed systemic antifungal therapy: a retrospective cross-sectional study. International Journal of Clinical Pharmacy. https://doi.org/10.1007/s11096-024-01788-w

Vancouver

Steinbrech J, Klein T, Kirschke S, Mannell H, Clauß S, Bertsche T, et al. Determining sensitivity and specificity of risk scores for QTc interval prolongation in hemato-oncology patients prescribed systemic antifungal therapy: a retrospective cross-sectional study. International Journal of Clinical Pharmacy. 2024. doi:10.1007/s11096-024-01788-w

BibTeX
@article{Steinbrech2024,
  author = {Steinbrech, Julian and Klein, Till and Kirschke, Stephanie and Mannell, Hanna and Clauß, Sebastian and Bertsche, Thilo and Strobach, Dorothea},
  title = {Determining sensitivity and specificity of risk scores for QTc interval prolongation in hemato-oncology patients prescribed systemic antifungal therapy: a retrospective cross-sectional study},
  journal = {International Journal of Clinical Pharmacy},
  year = {2024},
  doi = {10.1007/s11096-024-01788-w}
}
Kostenlos starten →